[CIS PIDD] [cis-pidd] pneumococcal vaccine strategy in adolescents & adults with immune deficiency
Klaus Warnatz
klaus.warnatz at uniklinik-freiburg.de
Fri Dec 6 00:56:18 EST 2013
Hi,
we just wrote the recommendations for the German society of rheumatologists and discussed this with different authorities and the companies.
I don't think we know the ideal time point for booster vaccination with PPV23. We finally wrote that one should wait at least 8 weeks before booster and apply it within in the first year. It is also recommended to booster patients how have received PPV23 in previous years with PCV13 subsequently and I am not convinced that the response is so dramatically affected that we can not do this in our patients where we use PPV23 for diagnostics. So we decided to continue using PPV23 for diagnostic testing in patients with suspected humoral ID. There is no hint that the previous conjugated vaccine decreases subsequent encounters with the unconjugated polysaccharide (so I don't think that we should have problems in the field of HiB.).
The upcoming problem however will be that in Germany all kids are now vaccinated with the PCV and therefore it will become questionable whether we can use PPV23 anymore in the future as a test for pure PnPS responses. Helen Chapel has therefore promoted the Salmonella vaccine, but we have no experience with it , so I can't tell.
greetings
klaus
Prof. Dr. med. Klaus Warnatz
UNIVERSITÄTSKLINIKUM FREIBURG
University Medical Center Freiburg
Center for Chronic Immunodeficiency
Division of Rheumatology and Clinical Immunology
Tel: +49-761-270-77640 / FAX -71000 / Pager: 12-7100
Breisacher Str. 117, 79106 Freiburg, Germany
klaus.warnatz at uniklinik-freiburg.de
http://www.uniklinik-freiburg.de/cci
Am 05.12.2013 um 22:43 schrieb Stan Ress:
> Hi Jack,
>
> I guess that ideally we hope to achieve both objectives! We do have adult patients with low baseline titres that responded well to pneumovax 23, in which case we would have shown B-cell competence and hopefully provided some extra protection against pneumococcal infection (admittedly they were not as severe as the 15 year-old girl with severe IgA deficiency & established bronchiectasis that I described). In patients that don’t respond, we will have added to the evidence of significant immune deficiency & helped to mount a case for funding for IVIG, although as you know, this conclusion seems to be controversial too.
>
> Routine vaccination of children with prevenar 13 has only fairly recently been performed in SA, for the past couple of years only. I have no experience with this, which prompted my query about whether we could do more to stimulate an effective antibody response in adults by using the protein conjugated vaccine. I don’t fully understand the concept of immune tolerance & waning protection in this latter scenario. Does the same also apply to Haemophilus B vaccination? We don’t have access to unconjugated vaccine and use Glaxo Hiberix (tetanus toxoid-conjugated haemophilus B). By the same logic, is this also setting the patient up for tolerance & waning protection against future encounter with native unconjugated Haemophilus B antigens?
>
> I’d really appreciate clarification on this as well.
>
> Many thanks & Regards,
>
> Stan
>
> --
> Stanley Ress
> Associate Professor of Medicine
> Head: Division of Clinical Immunology
> Department of Medicine
> H47 Old Main Building-room 26
> Groote Schuur Hospital and UCT
> Observatory 7925
> Cape Town
> South Africa
> TEL:INTERN. + 2721-4066201 or 4066197
> FAX: " + 2721-(0)865173095
> Cell: 0833115482
> email: stan.ress at uct.ac.za
>
>
>
>
> From: Bleesing, Jacob [mailto:Jack.Bleesing at cchmc.org]
> Sent: 05 December 2013 10:43 PM
> To: CIS-PIDD
> Subject: RE: [cis-pidd] pneumococcal vaccine strategy in adolescents & adults with immune deficiency
>
> Stan:
>
> You write: “Our policy has been to vaccinate such patients with 23-valent pneumococcal polysaccharide vaccine.” What is the purpose of this vaccination in such patients – to test his immune response or to provide active protection? If the latter, what makes you think he is going to benefit – given the fact that he has low IgG ELIZA antibodies, recurrent infections and bronchiectasis?
>
> I would just caution in following recommendations from resources such as ACIP when we are dealing with patients with immunodeficiency disorders or suspected immunodeficiency disorders.
>
> Regards,
>
> JB
>
>
>
> From: Boyce, Thomas G., M.D. [mailto:Boyce.Thomas at mayo.edu]
> Sent: Thursday, December 05, 2013 3:19 PM
> To: CIS-PIDD
> Subject: RE: [cis-pidd] pneumococcal vaccine strategy in adolescents & adults with immune deficiency
>
> This is true in adults. In children, you only need to wait 2 months.
>
> From: bounce-44205117-183824398 at lists.clinimmsoc.org [mailto:bounce-44205117-183824398 at lists.clinimmsoc.org] On Behalf OfStan Ress
> Sent: Thursday, December 05, 2013 2:11 PM
> To: CIS-PIDD
> Subject: RE: [cis-pidd] pneumococcal vaccine strategy in adolescents & adults with immune deficiency
>
> Hi Laia,
>
> I’d really like to hear what others think but what I understood from the ACIP statement is that, after PPSV23 vaccination, you need to wait at least one year before giving the 13-valent conjugate vaccine (Prevenar 13).
>
> Regards,
>
> Stan
>
> --
> Stanley Ress
> Associate Professor of Medicine
> Head: Division of Clinical Immunology
> Department of Medicine
> H47 Old Main Building-room 26
> Groote Schuur Hospital and UCT
> Observatory 7925
> Cape Town
> South Africa
> TEL:INTERN. + 2721-4066201 or 4066197
> FAX: " + 2721-(0)865173095
> Cell: 0833115482
> email: stan.ress at uct.ac.za
>
>
> From: Laia Alsina Manrique de Lara [mailto:lalsina at hsjdbcn.org]
> Sent: 05 December 2013 09:29 PM
> To: CIS-PIDD
> Cc: CIS-PIDD
> Subject: Re: [cis-pidd] pneumococcal vaccine strategy in adolescents & adults with immune deficiency
>
> OK,
> So how bad would it be to administer first Pneumovax23 to complete diagnosis, and if no response is observed, administer Prevenar13 for prophylactic purposes +/- IGRT?
>
> Laia Alsina
> Allergy and Clinical Immunology Department,
> Hospital Sant Joan de Deu, Barcelona.
>
> El 04/12/2013, a las 21:13, "John Ziegler" <j.ziegler at unsw.edu.au> escribió:
>
> Stan
>
> PPV23 as primary vaccine is still popular in this setting among my colleagues but I think it's unethical not to give PCV13 first.
>
> John
>
>
> _________________________
> Professor John B. Ziegler, AM
> Department of Immunology & Infectious Diseases
> Sydney Children's Hospital
> High St., Randwick NSW 2031
> Australia
> T: (02) 93821515
> F: + 61 + 2 93821580
> E: j.ziegler at unsw.edu.au
>
> On 5 Dec 2013, at 8:06 am, "Stan Ress" <stan.ress at uct.ac.za> wrote:
>
> Hi all,
>
> I have been referred a 15 year-old patient with extremely severe IgA deficiency, recurrent respiratory infections, & bronchiectasis on CT chest. Her baseline vaccine status revealed low IgG ELIZA antibodies against 4/5 antigens, including S. pneumonia & H. Influenza B. Our policy has been to vaccinate such patients with 23-valent pneumococcal polysaccharide vaccine. However, I saw a reference to ACIP recommendation that children & adults with immune compromising conditions or asplenia, should receive 13-valent conjugate vaccine 1st, followed 8 weeks later by unconjugated PPSV23.
>
> Is this the general current practise?
>
> Thanks.
> --
> Stanley Ress
> Associate Professor of Medicine
> Head: Division of Clinical Immunology
> Department of Medicine
> H47 Old Main Building-room 26
> Groote Schuur Hospital and UCT
> Observatory 7925
> Cape Town
> South Africa
> TEL:INTERN. + 2721-4066201 or 4066197
> FAX: " + 2721-(0)865173095
> Cell: 0833115482
> email: stan.ress at uct.ac.za
>
> UNIVERSITY OF CAPE TOWN
>
> This e-mail is subject to the UCT ICT policies and e-mail disclaimer published on our website athttp://www.uct.ac.za/about/policies/emaildisclaimer/ or obtainable from +27 21 650 9111. This e-mail is intended only for the person(s) to whom it is addressed. If the e-mail has reached you in error, please notify the author. If you are not the intended recipient of the e-mail you may not use, disclose, copy, redirect or print the content. If this e-mail is not related to the business of UCT it is sent by the sender in the sender's individual capacity.
> ---
>
> The CIS-PIDD listserv is supported by:
>
> <image001.jpg>
> The science & practice of human immunology
>
> P: +1.414.224.8095
> E: info at clinimmsoc.org
>
> Not a member of CIS? Please visit www.clinimmsoc.org to join!
>
> You are currently subscribed to cis-pidd as: j.ziegler at unsw.edu.au.
> To unsubscribe click here: http://lm.clinimmsoc.org/u?id=183824805.15fcb3e73d1784a002f4bfafdad280c5&n=T&l=cis-pidd&o=44201035
>
> ---
>
> The CIS-PIDD listserv is supported by:
>
> <image001.jpg>
> The science & practice of human immunology
>
> P: +1.414.224.8095
> E: info at clinimmsoc.org
>
> Not a member of CIS? Please visit www.clinimmsoc.org to join!
>
> You are currently subscribed to cis-pidd as: lalsina at hsjdbcn.org.
> To unsubscribe click here: http://lm.clinimmsoc.org/u?id=183824379.b100fe2a38d513f306e01a50580e257e&n=T&l=cis-pidd&o=44201076
>
>
> No imprimir aquest correu ajudarà a preservar el medi ambient.
> Si vostè no és el destinatari del missatge, o l'ha rebut per error, si us plau notifiqui-ho al remitent i destrueixi el missatge amb tot el seu contingut. Està prohibida la distribució no autoritzada del contingut d'aquest missatge.
>
> No imprimir este correo ayudará a preservar el medio ambiente.
> Si usted no es el destinatario del mensaje, o lo ha recibido por error, notifíquelo por favor al remitente y destruya el mensaje con todo su contenido. Está prohibida la distribución no autorizada del contenido de este mensaje.
> ---
>
> The CIS-PIDD listserv is supported by:
>
> <image001.jpg>
> The science & practice of human immunology
>
> P: +1.414.224.8095
> E: info at clinimmsoc.org
>
> Not a member of CIS? Please visit www.clinimmsoc.org to join!
>
> You are currently subscribed to cis-pidd as: stan.ress at uct.ac.za.
> To unsubscribe click here: http://lm.clinimmsoc.org/u?id=183824729.985c4c1fc1b701ae5f23bbbaa7fc60d8&n=T&l=cis-pidd&o=44204966
>
>
> ---
>
> The CIS-PIDD listserv is supported by:
>
> <image001.jpg>
> The science & practice of human immunology
>
> P: +1.414.224.8095
> E: info at clinimmsoc.org
>
> Not a member of CIS? Please visit www.clinimmsoc.org to join!
>
> You are currently subscribed to cis-pidd as: stan.ress at uct.ac.za.
> To unsubscribe click here: http://lm.clinimmsoc.org/u?id=183824729.985c4c1fc1b701ae5f23bbbaa7fc60d8&n=T&l=cis-pidd&o=44204966
>
> ---
>
> The CIS-PIDD listserv is supported by:
>
> <image002.jpg>
> The science & practice of human immunology
>
> P: +1.414.224.8095
> E: info at clinimmsoc.org
>
> Not a member of CIS? Please visit www.clinimmsoc.org to join!
>
> You are currently subscribed to cis-pidd as: boyce.thomas at mayo.edu.
> To unsubscribe click here: http://lm.clinimmsoc.org/u?id=183824398.f2b8412bd8ff7bcbcdffccce20d02a5f&n=T&l=cis-pidd&o=44205117
>
> ---
>
> The CIS-PIDD listserv is supported by:
>
> <image002.jpg>
> The science & practice of human immunology
>
> P: +1.414.224.8095
> E: info at clinimmsoc.org
>
> Not a member of CIS? Please visit www.clinimmsoc.org to join!
>
> You are currently subscribed to cis-pidd as: jack.bleesing at cchmc.org.
> To unsubscribe click here: http://lm.clinimmsoc.org/u?id=183824396.60ab2025d9ab67496282f5c977f33e12&n=T&l=cis-pidd&o=44205149
>
> ---
>
> The CIS-PIDD listserv is supported by:
>
> <image002.jpg>
> The science & practice of human immunology
>
> P: +1.414.224.8095
> E: info at clinimmsoc.org
>
> Not a member of CIS? Please visit www.clinimmsoc.org to join!
>
> You are currently subscribed to cis-pidd as: stan.ress at uct.ac.za.
> To unsubscribe click here: http://lm.clinimmsoc.org/u?id=183824729.985c4c1fc1b701ae5f23bbbaa7fc60d8&n=T&l=cis-pidd&o=44205190
>
> ---
>
> The CIS-PIDD listserv is supported by:
>
>
> The science & practice of human immunology
>
> P: +1.414.224.8095
> E: info at clinimmsoc.org
>
> Not a member of CIS? Please visit www.clinimmsoc.org to join!
>
> You are currently subscribed to cis-pidd as: klaus.warnatz at uniklinik-freiburg.de.
> To unsubscribe click here: http://lm.clinimmsoc.org/u?id=204020768.f427698a4bfd5db811f00eb2c8c003f5&n=T&l=cis-pidd&o=44205344
>
---
The CIS-PIDD listserv is supported by the Clinical Immunology Society
The science & practice of human immunology
P: +1.414.224.8095
E: info at clinimmsoc.org
Not a member of CIS? Please visit www.clinimmsoc.org to join!
You are currently subscribed to cis-pidd as: pagid at list.clinimmsoc.org.
To unsubscribe click here: http://lm.clinimmsoc.org/u?id=183939985.3ea13d40a15475ac00ebbd9cd8a37d6d&n=T&l=cis-pidd&o=44210562
or send a blank email to leave-44210562-183939985.3ea13d40a15475ac00ebbd9cd8a37d6d at lists.clinimmsoc.org
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://seven.pairlist.net/pipermail/pagid/attachments/20131206/095d853b/attachment.html>
More information about the PAGID
mailing list